Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Forest Laboratories, Inc. Announces Settlement Agreement with Hetero Labs Ltd. in BYSTOLIC® Patent Litigation



  Forest Laboratories, Inc. Announces Settlement Agreement with Hetero Labs
  Ltd. in BYSTOLIC® Patent Litigation

Business Wire

NEW YORK -- October 26, 2012

Forest Laboratories, Inc. (NYSE: FRX) and Forest Laboratories Holdings, Ltd.
(collectively, “Forest”) announced today that they have entered into a
settlement agreement with Hetero Labs Ltd. and Hetero USA Inc. (collectively,
“Hetero”) in patent infringement litigation brought by Forest in response to
Hetero’s ANDA seeking approval to market generic versions of Forest’s
BYSTOLIC® (nebivolol) tablets. Specifically, under the terms of the settlement
agreement and subject to review of the settlement terms by the U.S. Federal
Trade Commission, Forest will provide a license to Hetero that will permit it
to launch its generic version of BYSTOLIC® as of the date that is the later of
(a) three calendar months prior to the expiration of U.S. Patent No.
6,545,040, including any extensions and/or pediatric exclusivities or (b) the
date Hetero receives final FDA approval of its ANDA, or earlier in certain
circumstances. Similar patent infringement litigation brought by Forest
against Alkem Laboratories, Ltd., Indchemie Health Specialties Pvt. Ltd.,
Glenmark Generics Inc., Watson Pharmaceuticals Inc., Torrent Pharmaceuticals
Ltd., Amerigen Pharmaceuticals Ltd., and related companies and subsidiaries,
remains pending in a multidistrict litigation established in the U.S. District
Court for the Northern District of Illinois.

About Forest Laboratories

Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company
with a long track record of building partnerships and developing and marketing
products that make a positive difference in people’s lives. In addition to its
well-established franchises in therapeutic areas of the central nervous and
cardiovascular systems, Forest’s current pipeline includes product candidates
in all stages of development and across a wide range of therapeutic areas. The
Company is headquartered in New York, NY. To learn more about Forest
Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve a number of risks and
uncertainties, including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and
any subsequent SEC filings. Forest assumes no obligation to update
forward-looking statements contained in this release to reflect new
information or future events or developments.

Contact:

Forest Laboratories, Inc.
Frank J. Murdolo, 1-212-224-6714
Vice President - Investor Relations, Forest Laboratories, Inc.
media.relations@frx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement